Grifols, S.A.

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME Other stock markets 16:41:54 08/06/2026 BST			Pre-market 07:38:33
8.972 ^EUR	-0.95%		8.907	-0.72%

06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
05-28	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT

Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026

Published on 05/07/2026 at 07:36 pm BST

S&P Capital IQ

GRIFOLS, S.A.

-0.95%

Grifols, S.A. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was EUR 1,700 million compared to EUR 1,786 million a year ago. Net income was EUR 73 million compared to EUR 60 million a year ago.

Latest news about Grifols, S.A.

06-08	European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	MT
05-28	European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday	MT
05-26	Grifols' Insatiable Appetite
05-25	CaixaBank Trims Grifols' PT, Maintains Buy Rating	MT
05-22	European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading	MT
05-21	Spanish stocks - Factors to watch on May 21	RE
05-20	European Equities Traded in US as ADRs Rise in Wednesday Trading	MT
05-18	European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading	MT
05-15	PRESS DIGEST-Canada - May 18	RE
05-11	European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading	MT
05-08	Grifols: FCFs didn't impress; rebuilding trust isn't going to be easy
05-08	Moody's Changes Grifols Outlook to Positive	MT
05-08	Grifols Q1 Adjusted Profit Rises, Revenue Falls	MT
05-08	Spanish stocks - Factors to watch on May 8	RE
05-07	Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Chart Grifols, S.A.

Duration

Period

GRF: Dynamic Chart

Company Profile

Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (86.2%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (8.5%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.1%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.2%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.6%), European Union (15.9%), the United States and Canada (56.5%) and other (22%).

Employees

25,000

Sector

Pharmaceuticals

More about the company